Zessly® (infliximab) matched the reference medicine in terms of safety and efficacy at 54 weeks, even in patients who switched from the reference medicine to Zessly[1]Switching from the reference medicine to Erelzi® (etanercept) did not impact efficacy…
Sandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatologyPositive CHMP opinion based on comprehensive analytical, preclinical and clinica…
Sandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatologyPositive CHMP opinion based on comprehensive analytical, preclinical and clinica…
Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseasesEuropean Commission’s (EC) approval based on comprehensive data package confirming that Zessly® matches safety, eff…
Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseasesEuropean Commission’s (EC) approval based on comprehensive data package confirming that Zessly® matches safety, eff…
Holzkirchen, May 2, 2018 — Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics Licensing Application (BLA) for its proposed biosimilar rituximab…
Holzkirchen, May 2, 2018 — Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics Licensing Application (BLA) for its proposed biosimilar rituximab…
Net sales grew 4% (cc[1], +10% USD) mainly driven by:Entresto grew to USD 200 million, +126% (cc) driven by increased uptake world wideCosentyx was USD 580 million, +35% (cc) with strong growth in all indications and expanded accessOncology returned to…
Net sales grew 4% (cc[1], +10% USD) mainly driven by:Entresto grew to USD 200 million, +126% (cc) driven by increased uptake world wideCosentyx was USD 580 million, +35% (cc) with strong growth in all indications and expanded accessOncology returned to…
Deal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O™, potential treatment pending FDA clearance for patients with Opioid Use Disorder treated with buprenorphine Combines Sandoz expertise in launching…